Screener
EBIT at other companies
Other financials
Where this comes from
Calculated from Relmada Therapeutics, Inc.’s reported figures.
The source filing: Relmada Therapeutics, Inc.’s 10-Q, filed May 12, 2026. Open the filing →
- Filed
- May 12, 2026, 4:05 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001213900-26-055059
FAQ
- What is Relmada Therapeutics, Inc.'s EBIT?
- Relmada Therapeutics, Inc. (RLMD) reported EBIT of -$19.46M in Q1 2026.
- How has Relmada Therapeutics, Inc.'s EBIT changed year-over-year?
- Relmada Therapeutics, Inc.'s EBIT decreased by 6.8% year-over-year, from -$18.22M to -$19.46M.
- What is the long-term trend for Relmada Therapeutics, Inc.'s EBIT?
- Over 4 years (2021 to 2025), Relmada Therapeutics, Inc.'s EBIT has grown at a -17.2% compound annual growth rate (CAGR), from -$125.7M to -$59.1M.
- What does EBIT mean?
- Earnings before interest and taxes — the profit from the business before financing cost and tax. Uses reported operating income where a company reports it; otherwise pre-tax income plus interest expense. Lets companies be compared on earning power independent of capital structure.
Ask your AI about Relmada Therapeutics, Inc.'s ebit.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude